Introduction
Parkinson's disease is a common progressive neurodegenerative disorder, associated with a massive loss of dopaminergic cells that affects about 1% of the population over age 60 years. The study of patients at genetic risk of developing Parkinson's disease provides insight into early disease mechanisms that may help inform early diagnostic and intervention strategies (van der Brug et al., 2015) . We reported the recurrent hemizygous 22q11.2 deletion that is associated with 22q11.2 deletion syndrome (22q11.2DS, OMIM #192430, #188400) as a novel genetic risk factor for early-onset Parkinson's disease (Butcher et al., 2013) . Nearly 6% of 22q11.2DS patients over the age of 35 years were diagnosed with Parkinson's disease. The deletion has since been found to be enriched in early-onset Parkinson's disease cohorts and may account for $0.5% of all cases of early-onset Parkinson's disease (Mok et al., 2016) . The recurrent 22q11.2 deletion affects an estimated 1 in 4000 live births, usually occurring as a spontaneous mutation (McDonald-McGinn et al., 2015) . The Parkinson's disease phenotype in 22q11.2DS (22q11.2DS-Parkinson's disease) includes classic loss of midbrain dopaminergic neurons and variable Lewy body neuropathology Butcher et al., 2013; Mok et al., 2016) . Patients with 22q11.2DS-Parkinson's disease identified to date appear to show clinical symptoms, disease course, and treatment response similar to that of typical Parkinson's disease (Zaleski et al., 2009; Booij et al., 2010; Butcher et al., 2013; Rehman et al., 2015; Mok et al., 2016) . Manifestations of 22q11.2DS are multi-system and variable between patients, including birth defects, learning disabilities, endocrinological abnormalities, and seizures. Neuropsychiatric disorders, including those thought to involve dopaminergic dysfunction such as attention deficit disorder and schizophrenia, are common (Bassett et al., 2011; Fung et al., 2015; McDonaldMcGinn et al., 2015) .
There are as yet no systematic data on neuroimaging and clinical features of potential relevance to parkinsonism and Parkinson's disease in individuals with a 22q11.2 deletion. To begin to address this, we investigated adults with 22q11.2DS using standard assessments of motor and nonmotor functioning and neuroimaging relevant to Parkinson's disease including transcranial sonography and PET. For the PET, we selected 11 C-dihydrotetrabenazine ( 11 C-DTBZ), a vesicular monoamine transporter (VMAT2) radioligand used to assess striatal dopamine neuron density in other populations Bohnen et al., 2006; Martin et al., 2008; Christopher et al., 2014) . Healthy controls, and a single living patient with 22q11.2DS-Parkinson's disease, were assessed for comparison purposes.
We hypothesized that adults with 22q11.2DS at increased genetic risk of Parkinson's disease would exhibit a higher prevalence and/or severity of motor and nonmotor features believed to be associated with Parkinson's disease risk Siderowf and Lang, 2012; Berg et al., 2015) as well as neuroimaging features known to precede the clinical manifestation of Parkinson's disease, relative to healthy controls. These included enlarged substantia nigra echogenicity on transcranial sonography (Berg et al., 2013; Pilotto et al., 2015) and reduced striatal 11 C-DTBZ binding on PET neuroimaging . We expected that the 22q11.2DS-Parkinson's disease case would show a similar but more severe profile of symptoms and neuroimaging abnormalities.
Materials and methods

Participants and clinical evaluations
A total of 26 Canadian adults participated in this study. The main comparison groups comprised 13 individuals with 22q11.2DS ('22q11.2DS group') at increased age-related risk of Parkinson's disease (530 years) and 12 healthy age and sex-matched controls (Table 1) . As a positive control, we also assessed one previously unreported 50-year-old female patient with 22q11.2DS and early-onset Parkinson's disease. All participants were assessed using a battery of standard motor and non-motor assessments (Table 2) , transcranial sonography, and 11 C-DTBZ PET. None of the 26 participants had a first-degree family history of Parkinson's disease.
All patients with 22q11.2DS were recruited from a large cohort of adults with 22q11.2DS primarily ascertained through adult congenital cardiac, psychiatric, and genetic services using active screening and/or clinical referrals, where the 22q11.2 deletion had been molecularly confirmed using standard methods (Bassett et al., 2005; Van et al., 2016) . Microarray results available for 12 of the 13 subjects in the 22q11.2DS group showed the typical $2.5 Mb 22q11.2 deletion (LCR A-D) (Bassett et al., 2005; Costain et al., 2013) . The subject without microarray results had a confirmed 22q11.2 deletion with fluorescence in situ hybridization (FISH) using standard probes for the typical 22q11.2 deletion region. Healthy controls were recruited using advertisement and confirmed to be free of major neurological, psychiatric, or any other major illness using the Movement Disorders SocietyUnified Parkinson's Disease Rating Scale (MDS-UPDRS) Motor Examination, the Mini-International Neuropsychiatric Interview, the Mini-Mental State Examination, and a comprehensive medical history.
Psychiatric diagnoses in patients with 22q11.2DS were made using DSM-IV criteria, and previously established methods (Chow et al., 2006; Butcher et al., 2012; Van et al., 2016) . Nine (64.3%) patients had borderline to normal intellect and the remainder (n = 4, 30.8%) met DSM-IV criteria (Chow et al., 2006; Butcher et al., 2012; Van et al., 2016) for mild intellectual disability (Supplementary Table 1 ). Seven (53.8%) patients in the 22q11.2DS group were treated with an antipsychotic medication for a psychotic illness (Supplementary  Table 2 ): three patients were diagnosed with schizophrenia, two with schizoaffective disorder, and two with a psychotic mood disorder. Mean age at onset of psychosis was 25.3 [standard deviation (SD) = 7.2] years. Other current psychotropic medications in the 22q11.2DS group (Supplementary Table 1 ) included antidepressants (n = 9), benzodiazepines (n = 5), and anticonvulsants (n = 1).
The patient with 22q11.2DS-Parkinson's disease had a history of moderate intellectual disability and was treated for an anxiety disorder and a major depressive disorder with an antidepressant (Supplementary Table 1 ). There was no history of psychosis or treatment with an antipsychotic medication in this patient. The absence of known pathogenic point mutations in LRRK2, PARK2, PARK7/DJ-1, PINK1, or SNCA, or copy number variants in PARK2 or SNCA was confirmed using previously described methods (Butcher et al., 2013) . Clinical microarray testing showed a maternally inherited $500 kb 3q29 duplication (variant of unknown significance) in addition to the typical 22q11.2 deletion. This patient received a clinical diagnosis of L-DOPA responsive early-onset Parkinson's disease at age $48 years, following symptom onset at $45 years. L-DOPA treatment for this participant was withdrawn for 12 h prior to performing PET scanning and motor assessments.
Informed consent was obtained in writing and the study was approved by the research ethics boards at the Centre for Addiction and Mental Health and University Health Network, Toronto, Ontario, Canada.
Transcranial sonography
Bilateral transcranial sonography of the substantia nigra was independently performed by two experienced sonographers using a Siemens Acuson X300 PE and a 2.0-3.5 MHz transducer with a penetration depth of 14-16 cm and a dynamic range of 40-45 dB. Echogenicity measurements were performed off-line by a single sonographer. We selected the larger area of echogenicity in the substantia nigra of each participant or, in cases of an insufficient temporal bone window Tetralogy of Fallot/pulmonary atresia/ventricular septal defect, n = 2; tetralogy of Fallot, n = 1; ventricular septal defect, n = 1; sinus of Valsalva fistula/aneurysm, n = 1. Major depressive disorder, n = 5; generalized anxiety disorder, n = 4; obsessive compulsive disorder, n = 1 (Supplementary Table 1 ).
on one side (n = 3 each in the 22q11.2DS and control group), the area from the analysable side.
PET neuroimaging
Each subject had PET imaging using 11 C-DTBZ, a radioligand that binds to VMAT2. VMAT2 is a vesicular membrane protein that transports cytosolic dopamine (and other monoamines) into presynaptic vesicles (Lawal and Krantz, 2013) . The majority (495%) of VMAT2-related activity in the striatum derives from dopaminergic presynaptic terminals (Vander Borght et al., 1995; Wilson et al., 1996b) . VMAT2 binding is an established index of striatal dopamine neuron density in other populations Bohnen et al., 2006; Martin et al., 2008; Stoessl, 2011; Christopher et al., 2014) , based on evidence that striatal VMAT2 levels are a linear function of the number of dopaminergic neurons in the substantia nigra pars compacta (Vander Borght et al., 1995; Sun et al., 2012) , its strong correlation with striatal levels of the dopamine transporter, another presynaptic dopamine terminal marker, in healthy subjects (Sun et al., 2012) , and its robustness to both disease and drug compensatory regulation mechanisms (Vander Borght et al., 1995; Kilbourn et al., 1996; Wilson et al., 1996a; Kemmerer et al., 2003) .
PET scans were performed using a 3D high-resolution research brain tomograph (Siemens) as previously described (Christopher et al., 2014) . Following a 10-min transmission scan, the emission scans started with the bolus injection of 11 C-DTBZ (dose injected: 22q11.2DS group 9.91 AE 0.52 mCi versus control group 9.91 AE 0.81 mCi, P = 0.99; specific activity at time of injection: 22q11.2DS group 1674.8 AE 802.6 versus control group 2104.3 AE 1043.3 mCi/mmol, P = 0.26). Acquisition of emission data occurred over a period of 60 min. The emission list mode data were rebinned into a series of 3D sinograms. The data were normalized with attenuation and scatter correction before applying Fourier rebinning to convert the 3D sinograms into 2D sinograms, which were then reconstructed into image space using a 2D filtered back projection algorithm.
A region of interest analysis was performed for 11 C-DTBZ as described in Rusjan et al. (2006) using ROMI software. Our primary region of interest was the sensorimotor striatum (posterior putamen), which shows the earliest signs of dopamine depletion in Parkinson's disease. We also examined the Motor subscores were calculated from the MDS-UPDRS for all subjects as follows: bradykinesia (items 3.4 + 3.5 + 3.6 + 3.7 + 3.8 + 3.14), tremor (items 3.15 + 3.16 + 3.17), rigidity (item 3.3), and axial impairment (items 3.9 + 3.10 + 3.12 + 3.13).
d Four healthy controls had slight, clinically insignificant motor features.
e Hyposmia classified using age and sex-adjusted normative scores (http://sensonics.com/). Two (50%) of the controls with hyposmia and one (10%) of the 22q11.2DS patients with hyposmia were smokers.
f Adjusted for cognitive level (MoCA) due to test sensitivity to mild cognitive deficits (Bertrand et al., 2012) . One 22q11.2DS patient was unable to complete the 100-Hue Test due to comprehension difficulties.
associative (anterior putamen and caudate nucleus) and limbic (ventral striatum) striatal subdivisions (Martinez et al., 2003) . A standard brain template (International Consortium for Brain Mapping/Montreal Neurological Institute 152 MRI) containing predefined cortical and subcortical regions of interest (Talairach and Tournoux, 1988; Kabani et al., 1998) was non-linearly transformed using Statistical Parametric Mapping software (SPM8) to fit the individual high-resolution proton density weighted structural MRI scans (GE 3 T, oblique axial scan with 1 mm slice thickness).
Regions of interest were aligned and resliced to match the dimension of the PET images using a normalized mutual information algorithm.
11 C-DTBZ binding to VMAT2 (non-displaceable binding potential, BP ND ) was estimated in each region of interest using the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996) and the occipital cortex time activity curve as an input function Chan et al., 1999) using an in-house MATLAB script. The occipital cortex is the established region of reference (i.e. devoid of significant levels of VMAT2) (Tong et al., 2011) for 11 C-DTBZ imaging studies. The SRTM has been established as an appropriate model to quantify 11 C-DTBZ without arterial input function Chan et al., 1999) .
11 C-DTBZ binding after partial volume effects correction on time activity curve data using the Rousset algorithm (Rousset et al., 1998) was also assessed.
Statistical analyses
To compare demographic and clinical variables between the 22q11.2DS group and healthy controls, we used t-tests for independent continuous variables and Fisher's exact tests for independent categorical variables.
11 C-DTBZ binding in the regions of interest was contrasted between groups with analysis of covariance and corrected for multiple testing using a Bonferroni correction. An absolute lateralization index was calculated to investigate possible hemispheric asymmetry of 11 C-DTBZ binding (|right À left| / [right + left] / 2) for each region of interest and compared between groups using the same analysis of covariance approach. Spearman rank-order correlation coefficients were used to examine the putative relationships between regional 11 C-DTBZ binding and clinical symptoms. All statistical analyses were two-tailed and performed with SAS version 9.4 software (SAS Institute, Cary, NC), with statistical significance defined as P 5 0.05.
Results
Demographic and clinical features of the 22q11.2DS group at genetic risk of early-onset Parkinson's disease and healthy controls are presented in Table 1 . There were no significant between-group differences in age, sex, ethnicity, or handedness. The proportion of smokers was non-significantly greater in the control group. Patients with 22q11.2DS had a lower level of education and performed significantly worse on the Montreal Cognitive Assessment (MoCA) than controls, consistent with limitations in intellectual functioning as expected in 22q11.2DS (Chow et al., 2006; Bassett et al., 2011; Fung et al., 2015) .
Motor findings
Compared with the control group (Table 2) , the 22q11.2DS group had a significantly higher mean score on the MDS-UPDRS Motor Exam subscale (P = 0.0004) and the associated bradykinesia (P = 0.008), tremor (P = 0.032), and axial impairment (P = 0.002) subscores and performed significantly worse on the Purdue Pegboard test (dominant hand, P = 0.0002; non-dominant hand, P = 0.004).
Each subject in the 22q11.2DS group exhibited at least one parkinsonian sign on the MDS-UPDRS motor exam (Supplementary Table 2 ). Bradykinesia was the most commonly observed, affecting 11 (84.6%) of the 13 patients, including all six with no history of antipsychotic treatment. Four subjects (23.1%) had rigidity, four (30.8%) postural instability, and eight (61.5%) action tremor, of whom one, three, and four, respectively, had no antipsychotic treatment. Eight patients (61.5%), and no healthy controls, were clinically classified by the assessing movement disorders specialist to have parkinsonism (Supplementary  Table 2 ). Of these, two had no antipsychotic treatment.
Non-motor findings
There was a significantly greater proportion of 22q11.2DS patients with hyposmia (n = 10, 76.9%) compared with controls (n = 4, 33.3%; P = 0.047), although results were non-significant if smokers (n = 1 22q11.2DS; n = 5 controls) were excluded (n = 9 hyposmia, 75.0% versus n = 2, 28.5%; P = 0.074). Hyposmia was absent (n = 2) or mild (n = 3) in the 22q11.2DS patients without parkinsonism. In contrast, six of the eight patients with parkinsonism had moderate to severe hyposmia, and the patient with 22q11.2DS-Parkinson's disease met criteria for anosmia (Supplementary Table 2 ). Although performance was worse on the 100-Hue test of colour discrimination in the 22q11.2DS group (Table 2) , there was no significant between-group difference after adjusting for cognitive level (MoCA scores). One participant in each group self-reported symptoms of REM sleep behaviour disorder (Nightingale et al., 2005) by endorsing that they moved while asleep as if acting out their dreams, that they had injured themselves or a bed partner while asleep, and that those movements woke them from sleep.
Neuroimaging findings
As hypothesized, the mean area of substantia nigra echogenicity on transcranial sonography was significantly larger in the 22q11.2DS at-risk of Parkinson's disease group than the healthy control group (0.18 cm C-DTBZ binding was 36.7% higher in the sensorimotor striatum (3.50, SD = 0.96) relative to the control group (2.56, SD = 0.48; P = 0.006), 34.9% higher in the associative striatum (22q11.2DS 3.40, SD = 0.70; controls 2.52, SD = 0.43; P = 0.001), and 30.9% higher in the limbic striatum (22q11.2DS 2.71, SD = 0.42; controls 2.07, SD = 0.30; P = 0.0003). Results were similar after implementing a partial volume effects correction on time activity curve data (results not shown). Also, within the 22q11.2DS group, comparing patients with and without psychosis, there were no significant differences for striatal BP ND values (P 4 0.6), or laterality index calculated for hemispheric 11 C-DTBZ binding (P 4 0.3), for any of the three striatal subdivisions. Median 11 C-DTBZ binding was similar in patients with 22q11.2DS at-risk of Parkinson's disease with (n = 9) and without (n = 4) treatment with an antidepressant medication (sensorimotor striatum, 3.81 versus 3.74; associative striatum, 3.39 versus 3.78; limbic striatum, 2.68 versus 2.56, respectively). There were no gross structural abnormalities in the striatum or the occipital lobe reference region in the 22q11.2DS or control groups as assessed with MRI. As expected, time-activity curves calculated using decay-corrected standard uptake values for the occipital reference region showed no significant difference between patients and controls (two-way repeated measures ANOVA, P = 0.26; Supplementary Fig. 1 ).
There was no support for a correlation between MDS-UPDRS bradykinesia subscores and 11 C-DTBZ binding in the associative (r = 0.03, P = 0.92) or limbic (r = À 0.13, P = 0.68) striatum. In the sensorimotor striatum, there was a negative, though non-significant, correlation (r = À0.43, P = 0.14; Fig. 3 ). Including the patient with 22q11.2DS-Parkinson's disease as a measure of an advanced motor disease state strengthened the linear relationship between bradykinesia and 11 C-DTBZ binding (r = À0.54, P = 0.04) in the sensorimotor striatum. No relationships were found between 11 C-DTBZ binding in the three striatal regions and other motor measures.
Discussion
Here we report the results of the first investigation of phenotypes relevant to Parkinson's disease in individuals with a hemizygous 22q11.2 deletion, a genetic risk factor for early-onset Parkinson's disease (Butcher et al., 2013; Mok et al., 2016) . As hypothesized, we found that parkinsonian features and olfactory deficits were more common in adults with 22q11.2DS relative to healthy age and sexmatched controls. Transcranial sonography, a proposed neuroimaging risk marker of Parkinson's disease (Berg et al., 2013; Pilotto et al., 2015) , revealed significantly greater substantia nigra echogenicity in the 22q11.2DS group relative to controls. PET neuroimaging with 11 C-DTBZ, an established index of striatal dopamine neuron density in other populations Bohnen et al., 2006; Martin et al., 2008; Christopher et al., 2014) , showed a novel result: elevated 11 C-DTBZ binding The mean echogenic area (horizontal line) corresponding to the anatomical location of the substantia nigra was significantly larger in the 22q11.2DS at-risk group compared with the age and sex-matched control group. The area of echogenicity in the substantia nigra in the 22q11.2DS-PD case is shown for comparison purposes. Zero measurements indicate instances where the mesencephalic brainstem was clearly visualized but there was no measurable echogenic signal in the location of the substantia nigra. The bilateral temporal bone window was insufficient in one 22q11.2DS patient. *P 4 0.05. levels in the striatum in the 22q11.2DS group relative to healthy age and sex-matched controls. Interestingly, we found that a PET study using a presynaptic dopamine transporter ligand ( 18 F-PRO4.MZ) of a 45-year-old female with 22q11.2DS and parkinsonism with severe periodic limb movement disorder from another centre showed similarly elevated (by 30%) bilateral uptake in the putamen and caudate nuclei (see Supplementary material for case history). We propose that these initial findings suggest that manifestations of parkinsonism and/or evolution to Parkinson's disease in this genetic population may include a hyperdopaminergic mechanism. We discuss the findings and potential implications below.
Motor and olfactory dysfunction in 22q11.2DS
The motor functioning deficits documented in this study in individuals with 22q11.2DS, most notably bradykinesia and postural and/or kinetic tremor, may help inform clinical care of the growing adult 22q11.2DS population and could potentially help to identify predictive markers of Parkinson's disease in 22q11.2DS. The deficits observed could represent clinical manifestations of 22q11.2DS in adulthood in the absence of Parkinson's disease risk. Only a small subset of individuals might be expected to progress to Parkinson's disease given the reduced penetrance of Parkinson's disease in 22q11.2DS (Butcher et al., 2013) . A spectrum of motor dysfunction may therefore be part of the variable clinical presentation of 22q11.2DS , in keeping with the variable expressivity of other 22q11.2DS phenotypes (Fung et al., 2015) .
Other 22q11.2DS-associated comorbidities and/or treatments, including most notably schizophrenia, epilepsy, and neuroendocrine disorders, may contribute to observed abnormalities in motor functioning in adulthood. These will require careful study to evaluate their relative contributions to the neurological presentation of adults with 22q11.2DS Fung et al., 2015) . Motor deficits were not, however, wholly attributable to antipsychotic treatment as they were also observed in patients who were not receiving these medications. Longitudinal follow-up of the patients studied may help reveal which, if any, of the observed motor phenotypes may be useful predictors of risk of progression to Parkinson's disease in patients with 22q11.2DS Berg et al., 2015) .
With respect to possible non-motor features associated with Parkinson's disease, the results for hyposmia may suggest that olfactory dysfunction could be associated with Parkinson's disease risk in 22q11.2DS, as in other forms of Parkinson's disease (Siderowf and Lang, 2012; Berg et al., 2015) . Olfactory deficits appear to be prevalent in children and adults with 22q11.2DS (Sobin et al., 2006; Bassett et al., 2007; Romanos et al., 2011) . In typical Parkinson's disease, the olfactory deficit seems to occur closer to the onset of clinically identifiable parkinsonism than some other premonitory features of Parkinson's disease (Marras et al., 2005) . The occurrence of olfactory deficits in patients with 22q11.2DS, even in childhood, may suggest that olfactory deficits could potentially be a useful early feature in evaluating risk of Parkinson's disease in 22q11.2DS. This possibility will need to be evaluated in adequately powered longitudinal studies. FarnsworthMunsell Hue test results may reflect a tendency for 22q11.2DS patients to have worse colour vision, although it appears that cognitive dysfunction may have compromised performance on this test (Bertrand et al., 2012) . Sleep disorders may be a less prevalent early feature of 22q11.2DS-Parkinson's disease and/or represent the pleiotropy that appears to be a normal aspect of this condition (Bassett et al., 2011) . Formal sleep studies are needed to clarify this.
The finding of a larger mean echogenic signal in the 22q11.2DS group is consistent with what would be expected for a group at increased risk of developing Parkinson's disease (Berg, 2011; Pilotto et al., 2015) and suggests the potential utility of transcranial sonography as a Parkinson's disease risk assessment tool in this population. However, the relatively small number of subjects and methodological limitations preclude the interpretation of the echogenic signal size as a risk indicator for any individual subject. Although the presence of substantia nigra hyperechogenicity appears to have good positive predictive value in patients with already well-characterized Parkinson's disease (Berg, 2011; Berg et al., 2013) , an enlarged echogenic signal is not specific to Parkinson's disease risk and poor diagnostic sensitivity appears to be a particular issue in patients in the early stages of the disease (Bouwmans et al., 2013; Liu et al., 2014) . Consistent with these prior findings there was no evidence of an enlargement of the echogenicity signal in the 22q11.2DS Parkinson's disease patient. Adequately powered longitudinal studies are needed.
Imaging of VMAT2 in 22q11.2DS
The 22q11.2DS patient diagnosed with early-onset Parkinson's disease in this study showed the typical pattern found for other patients diagnosed with Parkinson's disease: markedly reduced striatal 11 C-DTBZ binding, reflecting loss of dopamine terminals Bohnen et al., 2006; Martin et al., 2008; Christopher et al., 2014) . This was most prominent in the putamen, as in typical Parkinson's disease (Bohnen et al., 2006; Martin et al., 2008) . This finding is also consistent with the severe striatal dopamine denervation observed on neuropathology (Butcher et al., 2013) and dopamine transporter imaging Mok et al., 2016) 
How then to interpret the novel finding that the 22q11.2DS at-risk group, many with parkinsonian features but no diagnosis of Parkinson's disease, showed mean elevated striatal 11 C-DTBZ binding relative to controls? The clinical features and abnormal 11 C-DTBZ binding may possibly suggest the manifestation of a parkinsonian syndrome related to dopaminergic dysfunction in this genetic population. Given that these patients have the potential to develop Parkinson's disease, these results also raise the possibility that early stages of dopaminergic degeneration in 22q11.2DS-associated Parkinson's disease could be masked by higher pre-morbid 11 C-DTBZ binding (Fig. 4) . A possible implication is that the utility of presynaptic dopaminergic neuroimaging in helping to distinguish between Parkinson's disease and non-degenerative forms of Parkinson's disease (e.g. drug-induced parkinsonism) in patients with 22q11.2DS may be limited to later stages of the disease when significant presynaptic dopaminergic terminal loss has occurred Mok et al., 2016) . Interestingly, two patients in the 22q11.2DS group at-risk of Parkinson's disease (Cases 7 and 13) would fulfil the new clinical MDS criteria for Parkinson's disease , though such a diagnosis would seemingly conflict with the 11 C-DTBZ PET results. Both exhibited bradykinesia, rigidity (neck), and hyposmia. Subsequent to the clinical and imaging study assessments, significant decline in motor and cognitive functioning continued in Case 13 , who notably exhibited the lowest level of striatal 11 C-DTBZ binding among the 22q11.2DS at-risk group, but whose 11 C-DTBZ binding levels were not reduced relative to healthy controls (Figs 2 and 3) . He has shown an unequivocal improvement in symptoms following recent initiation of levodopa/carbidopa treatment (100/25 mg three times a day), approximately 3 years after his 11 C-DTBZ PET scan. Improvements included reduced manual bradykinesia, a faster and more fluid gait, and an almost complete resolution of prominent drooling and a jerky upper limb postural and action tremor. His range of facial expression was also slightly improved, together with apparent resolution of facial action myoclonus. These results illustrate the need for larger longitudinal studies to delineate the spectrum and aetiology of the neurological phenotype in adults with 22q11.2DS to help inform diagnostic and treatment strategies for this complex genetic population.
The evidence of increased levels of 11 C-DTBZ binding in 22q11.2DS could be a finding unique to this particular patient population at-risk of developing Parkinson's disease. As yet, there have been few studies of patients at high risk of Parkinson's disease prior to clinical onset using 11 C-DTBZ PET neuroimaging (Adams et al., 2005; Sossi et al., 2010) . Relative to controls, asymptomatic LRRK2 mutation carriers (Adams et al., 2005; Sossi et al., 2010) and individuals with REM sleep behaviour disorder (Albin et al., 2000) , who are known to be atrisk for Parkinson's disease, show evidence of reduced striatal VMAT2 levels using 11 C-DTBZ, consistent with a prodromal loss of striatal dopaminergic innervation (Albin et al., 2000; Adams et al., 2005; Sossi et al., 2010) . The unexpected finding here of increased average striatal 11 C-DTBZ binding levels in young/middle-aged adults with 22q11.2DS could perhaps be a general feature of 22q11.2DS that is unrelated to the pathogenesis of parkinsonism or Parkinson's disease. Given the plausibility of hyperdopaminergia as a potential pathophysiologic mechanism of Parkinson's disease (Bisaglia et al., 2013; Goldstein et al., 2014) however, it is possible that these 22q11.2DS patients may have been studied at an earlier stage than other at-risk groups along a trajectory toward the typical hypodopaminergia of manifest Parkinson's disease. Also, advances in genetics suggest there are likely to be numerous molecular pathways to the common endpoint of clinically manifest Parkinson's disease (Lin and Farrer, 2014; van der Brug et al., 2015) . Hyperdopaminergia may be but one of these.
If in 22q11.2DS there is a baseline hyperdopaminergic state that precedes the onset of dopaminergic denervation, this could be consistent with the chronic exposure to the neurotoxic properties of dopamine and its metabolites that has been proposed to be involved in Parkinson's disease pathogenesis (Bisaglia et al., 2013; Goldstein et al., 2014) . Animal models have shown that dopamine autotoxicity can lead to progressive neurodegeneration of nigrostriatal neurons through mechanisms involving increased oxidative stress (Hastings et al., 1996; Goldstein et al., 2014) . In 22q11.2DS, the increased availability of presynaptic dopamine in the striatum suggested by the finding of elevated 11 C-DTBZ binding may be interacting with, or compounded by, a deficient dopamine clearing mechanism related to the effects of missing one copy of the COMT gene that is located in 22q11.2 deletion region (Boot et al., 2008 (Boot et al., , 2011 . COMT encodes an enzyme involved in dopamine degradation. Also, impaired mitochondrial function related to hemizygosity of the six genes in the deletion region that are involved in mitochondrial function (MRPL40, PRODH, SLC25A1, TANGO2, TXNRD2, and ZDDHC8) may further contribute to increased oxidative stress and vulnerability to dopaminergic cell death in 22q11.2DS. The finding of a significantly larger area of substantia nigra echogenicity in the 22q11.2DS group relative to controls could be consistent with a mechanism involving oxidative stress, given the association of such echogenicity with higher iron tissue levels that may enhance the generation of reactive oxygen species (Berg et al., 2002) .
There are several possible mechanisms that could mediate the finding of elevated 11 C-DTBZ binding in 22q11.2DS. In other populations, 11 C-DTBZ binding to VMAT2 is a wellestablished index of striatal dopamine neuron density Bohnen et al., 2006; Martin et al., 2008; Christopher et al., 2014) . Our findings could therefore represent a consequence of excess striatal dopaminergic innervation in 22q11.2DS. If true, increased binding of radioligands specific to the presynaptic plasmalemma dopamine transporter, another measure of striatal presynaptic terminal density (Stoessl, 2011; Sun et al., 2012) , would also be expected. The observation of increased 18 F-PRO4.MZ binding in a patient with 22q11.2DS (Supplementary material) from an independent centre is consistent with this prediction. Abnormal striatal innervation could occur, for example, through a neurodevelopmental mechanism such as reduced pruning in 22q11.2DS (Gothelf et al., 2007) . Elevated 11 C-DTBZ binding in 22q11.2DS could also reflect increased availability of presynaptic dopamine storage vesicles through an increase in the number of dopamine storage vesicles per synaptic terminal, more densely packed vesicles, or larger synaptic terminals in 22q11.2DS. Post-mortem studies in patients with 22q11.2DS without Parkinson's disease could clarify these findings. Brain tissue of adults with 22q11.2DS, however, remains an extremely rare resource (Butcher et al., 2013) .
Alternatively, it could be hypothesized that elevated 11 C-DTBZ binding (and 18 F-PRO4.MZ binding) is the result of compensatory changes that may occur in response to a deficient dopamine clearing mechanism in 22q11.2DS (Boot et al., 2008 (Boot et al., , 2011 , as noted above, related to COMT haploinsufficiency, and to potential cytotoxic effects of dopamine. Overexpression of VMAT2 in mice has been found to increase vesicular capacity for dopamine and confer a protective effect against dopamine terminal damage and nigral cell loss induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Lohr et al., 2014) . Under normal conditions, COMT seems to play a relatively minor role in dopamine clearance in the striatum, and striatal dopamine levels in Comt knockout mice have been shown to be normal (Huotari et al., 2002) . However, the role of COMT in striatal dopamine degradation may be more important under some challenged conditions. For example, rats treated with a COMT-selective inhibitor showed larger increases in striatal dopamine when challenged with L-DOPA compared with controls (Brannan et al., 1992) . It is possible that our findings were influenced by altered striatal VMAT2 expression in 22q11.2DS related to COMT haploinsufficiency or other 22q11.2DS-associated conditions and/or their treatments. However, there are extensive animal data suggesting that levels of VMAT2 are relatively resistant to compensatory regulation, e.g. when compared with other dopamine markers such as the dopamine transporter (Vander Borght et al., 1995; Kilbourn et al., 1996; Wilson et al., 1996a; Kemmerer et al., 2003) . There is no evidence as far as we are aware to suggest that the 22q11.2 deletion confers a reduction in presynaptic intravesicular dopamine concentration and reduced competition for the same binding site on VMAT2 that could lead to the elevated 11 C-DTBZ binding observed in patients with L-DOPA responsive dystonia or in recently abstinent methamphetamine users (De La Fuente-Fernandez et al., 2003; Boileau et al., 2008) . A resting state study that used single-photon emission computed tomography and 123 I-IBZM to investigate postsynaptic striatal dopamine D 2 receptor binding showed no abnormalities in adults with 22q11.2DS without psychotic illness or Parkinson's disease . One could speculate that low vesicular dopamine levels would predict poor tolerability of antipsychotics, particularly those with high affinity to the dopamine D 2 receptor; these medications are widely used to successfully treat psychotic illness in 22q11.2DS (Fung et al., 2015) .
Interestingly, a hyperdopaminergic dysfunction mechanism could contribute to vulnerability to neurodevelopmental disorders such as schizophrenia and attention deficit disorder that are associated with 22q11.2DS (Bassett et al., 2011; Fung et al., 2015; McDonald-McGinn et al., 2015) . One could posit that in 22q11.2DS there may be a developmental deficit in pruning of dopaminergic neurons associated with increased risk for expression of schizophrenia, followed by neurotoxicity related to a relatively hyperdopaminergic state with (later) increased risk for expression of Parkinson's disease. The single previous PET study using 11 C-DTBZ binding in patients with idiopathic schizophrenia reported no difference in striatal 11 C-DTBZ binding relative to controls (Taylor et al., 2000) , in keeping with a recent meta-analysis of dopamine transporter binding studies that found no evidence of altered density of presynaptic dopamine terminals in idiopathic schizophrenia (FusarPoli and Meyer-Lindenberg, 2013) . The preliminary observation in the current study of similar 11 C-DTBZ binding levels between 22q11.2DS patients with and without a psychotic illness warrants investigating in a larger, adequately powered cohort.
Strengths and limitations
The results of this study provide the first assessment of phenotypes relevant to Parkinson's disease in patients at risk of a 22q11.2DS form of Parkinson's disease. The study of patients at genetically increased risk of developing Parkinson's disease can provide the opportunity to investigate early biomarkers of the disease and the natural history of this complex disease and its potential mechanisms (Marras et al., 2011; van der Brug et al., 2015) .
Longitudinal studies are needed to evaluate whether the observed motor symptoms, olfactory deficits, and neuroimaging features are relevant to early-onset Parkinson's disease risk in 22q11.2DS and/or their role as part of the variable clinical presentation of 22q11.2DS in adulthood.
The results of this study unexpectedly demonstrated that, on average, 11 C-DTBZ binding was elevated in a group of patients with 22q11.2DS relative to a group of healthy controls. As expected given the typical variability observed in PET neuroimaging studies, the 11 C-DTBZ binding level values in the 22q11.2DS group overlapped with the binding level of the control subjects. Moreover, variability in expression of phenotypes is common in 22q11.2DS (Bassett et al., 2011; Fung et al., 2015; McDonald-McGinn et al., 2015) . Well-powered prospective studies will be needed to determine the normative range of 11 C-DTBZ binding in 22q11.2DS and to evaluate any clinical significance of striatal 11 C-DTBZ binding levels. Motor assessments were not completed blind to 22q11.2 deletion status as 22q11.2DS patients are often clinically identifiable from features such as hypernasal speech and mild dysmorphic features. However, all motor assessments were performed blind to olfactory and PET imaging results. It is possible that if patients with 22q11.2DS with motor problems were more likely to volunteer for the study this may have influenced the proportion observed to have motor dysfunction. Although all results were limited by the relatively small sample size of this genetic at-risk group, several significant differences were detectable relative to controls. Larger samples may also reveal differences of smaller effect size.
With respect to the 11 C-DTBZ binding potential results, minor structural brain differences in patients with 22q11.2DS relative to controls would not be expected to account for the large differences observed. Moreover, partial volume effects correction on time activity curve data showed similar results. Although several subjects in the 22q11.2DS group at-risk of Parkinson's disease were treated with an antidepressant, results were similar in those with and without antidepressant treatment. It has been previously shown that VMAT2 levels in the rat brain are not modified by chronic treatment with the antidepressant paroxetine (Vilpoux et al., 2000) . Importantly, we found no difference in the time activity curve of reference region (occipital cortex) between patients and controls that could have explained our results. This provides some assurance that the finding of elevated striatal 11 C-DTBZ binding in the 22q11.2DS group is extremely unlikely to be due to a quantification artefact related to the use of the occipital cortex to calculate BP ND . It has previously been shown that levels of VMAT2 are 4100-fold lower in postmortem human cerebral neocortices than in the striatum, and are unlikely to be detected by 11 C-DTBZ (Tong et al., 2011) . On the other hand, Koeppe et al. (1999) found that $5% of the cortical 11 C-DTBZ PET signal could come from specific binding [BP ND (cortex) = $0.06]. Thus, conservatively assuming a scenario where the observed differences in binding in our study were affected by this level of specific binding in the occipital cortex [healthy controls, BP ND (occipital cortex) = 0.06 and BP ND (striatum) = 2.5; 22q11.2DS group, cortical BP ND (occipital cortex) = 0 and BP ND (striatum) = 2.5], no more than 11% of the difference observed between 22q11.2DS patients and controls could be explained. If an even higher BP ND of 0.16 was assumed for the occipital region for the healthy control group, the case-control difference in 11 C-DTBZ binding would be 23%, which is still lower than the observed differences of 4 30%. Neuropathological studies assessing VMAT2 protein distribution and other markers of neurotransmitter systems in patients with 22q11.2DS would further aid the interpretation of our PET findings.
Conclusions
Adults with 22q11.2DS 5 30 years who are at increased risk of developing early-onset Parkinson's disease due to hemizygosity of the 22q11.2 deletion region demonstrate variable expression of features associated with Parkinson's disease. These may include motor and olfactory deficits and larger average echogenicity on transcranial sonography, relative to healthy controls. The finding of elevated levels of striatal 11 C-DTBZ binding, a radioligand for presynaptic dopamine vesicles, suggest that this genetically at-risk patient population is affected by a hyperdopaminergic abnormality. We hypothesize that the increased risk for developing Parkinson's disease in individuals with 22q11.2DS may involve an autotoxicity mechanism related to this dopaminergic dysfunction. Longitudinal studies are needed to evaluate the potential prognostic significance of these initial cross-sectional findings in the context of the clinical presentation of 22q11.2DS in adulthood. Animal studies using available 22q11.2DS models could help evaluate mechanisms and test novel treatments.
